Table. Visual Acuity and Central Subfield Thickness Outcomes.
| Outcome | Aflibercept Study Arm | Bevacizumab Study Arm | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Monthly Group | Treat-and-Extend Group | Estimate of Difference Between Groups (CI) | P Value | Monthly Group | Treat-and-Extend Group | Estimate of Difference Between Groups (CI) | P Value | |||||
| No. (%) | Mean (SD) | No. (%) | Mean (SD) | No. (%) | Mean (SD) | No. (%) | Mean (SD) | |||||
| Visual acuity letter score | ||||||||||||
| 6 mo | 79 (100) |
72.1 (15.7) |
80 (100) |
72.0 (17.0) |
67 (100) |
73.8 (12.3) |
67 (100) |
74.4 (13.0) |
||||
| 12 mo | 78 (99) |
72.7 (17.3) |
76 (95) |
71.6 (16.4) |
1.85 (−3.42 to 7.12)a |
.49 | 66 (99) |
75.2 (13.1) |
65 (97) |
74.0 (14.0) |
1.27 (−3.31 to 5.85)a |
.59 |
| Change from month 6 to 12b | 78 (99) |
0.8 (10.5) |
76 (95) |
−1.2 (9.2) |
1.88 (−1.07 to 4.86)c |
.15 | 66 (99) |
1.6 (8.9) |
65 (97) |
-0.4 (9.8) |
1.98 (−1.08 to 5.03)c |
.15 |
| Central subfield thickness (μm)d | ||||||||||||
| 6 mo | 77 (97) |
223 (43) |
74 (93) |
225 (48) |
66 (99) |
261 (79) |
67 (100) |
251 (71) |
||||
| 12 mo | 72 (91) |
237 (108) |
72 (90) |
238 (84) |
−3.52 (−28.25 to 21.21)a |
.78 | 64 (96) |
245 (64) |
64 (96) |
268 (130) |
−25.77 (−60.61 to 9.07)a |
.15 |
| Change from month 6 to 12 | 71 (90) |
12.5 (105.8) |
68 (85) |
15.1 (85.1) |
−5.2 (−26.87 to 16.47)a |
.64 | 64 (96) |
−16.2 (74.5) |
64 (96) |
17.1 (109.8) |
−35.01 (−63.95 to −6.07)a |
.02e |
| Resolution of macular edema | No./Total No. (%) | No./ Total No. (%) |
Odds Ratio (95% CI) |
No./ Total No. (%) | No./ Total No. (%) |
Odds Ratio (95% CI) |
||||||
| 6 mo | 50/78 (64) |
42/78 (54) |
23/67 (34) |
26/67 (39) |
||||||||
| 12 mo | 38/73 (52) |
28/74 (38) |
1.18 (0.61 to 2.26) |
.62 | 23/66 (35) |
26/64 (41) |
0.71 (0.35 to 1.42) |
.33 | ||||
a
95% CI.
b
The primary outcome was the mean difference in treatment group outcomes (monthly minus TAE) from month 6 to 12.
c
97.5% CI.
d
Central subfield thickness scores were obtained via spectral-domain optical coherence tomography.
e
Not significant after correction for multiple testing.